STOCK TITAN
  1. Home
  2. Sec-filings
  3. LIXT
  4. [8-K] LIXTE BIOTECHNOLOGY HOLDINGS, INC. Reports Material Event

Lixte (NASDAQ: LIXT) lifts CEO Geordan Pursglove base salary to $360k

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Lixte Biotechnology Holdings, Inc. updated its executive compensation by amending the employment agreement of Chief Executive Officer Geordan Pursglove. Effective January 1, 2026, his annual base salary increased from $240,000 to $360,000, as approved by the Compensation Committee and Board of Directors. The salary Amendment, dated March 18, 2026, is filed as Exhibit 10.1 and incorporated by reference into this report.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Understanding 8-K Material Events →
false 0001335105 0001335105 2026-03-18 2026-03-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): March 18, 2026

 

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

delaware   001-39717   20-2903526

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification Number)

 

433 Plaza Real, Suite 275

Boca Raton, Florida 33432

(Address of principal executive offices)

 

(631) 830-7092

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   LIXT   The NASDAQ Stock Market, LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On March 18, 2026, Lixte Biotechnology Holdings, Inc., (the “Company”), and Geordan Pursglove, the Company’s Chief Executive Officer (the “CEO”), entered into an Amendment to the Employment Agreement (the “Amendment”). The original employment agreement (the “Employment Agreement”) between the Company and the CEO was entered in on June 16, 2025.

 

Pursuant to the Amendment, the CEO’s annual base salary was increased from $240,000 to $360,000 effective as of January 1, 2026. The Amendment was approved by the Company’s Compensation Committee and Board of Directors.

 

The Amendment is being filed as an exhibit to this Current Report on Form 8-K and is incorporated herein by reference. The foregoing description does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, which is filed herewith as Exhibit 10.1.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits. The following exhibits are filed herewith.

 

Exhibit

Number

   Description
10.1   Amendment to Employment Agreement dated March 18, 2026, between Lixte Biotechnology Holdings. Inc., and Geordan Purglove.
104   Cover Page Interactive Data File (embedded within the inline XBRL Document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 20, 2026 LIXTE BIOTECHNOLOGY HOLDINGS, INC.
  (Registrant)
     
  By: /s/ Geordan Pursglove
    Geordan Pursglove
    Chairman of the Board and Chief Executive Officer

 

 

 

Source: View Original Filing on SEC EDGAR

FAQ

What executive compensation change did Lixte Biotechnology (LIXT) disclose?

Lixte Biotechnology disclosed an amendment to CEO Geordan Pursglove’s employment agreement, raising his annual base salary from $240,000 to $360,000, effective January 1, 2026. The change was formally approved by the Compensation Committee and Board of Directors and documented in a written amendment.

When does Lixte’s new CEO salary for Geordan Pursglove take effect?

The increased base salary for CEO Geordan Pursglove is effective as of January 1, 2026. Although the Amendment itself is dated March 18, 2026, it applies retroactively to the beginning of 2026, as specified in the company’s disclosure and related exhibit.

How much did Lixte Biotechnology increase its CEO’s base salary?

Lixte Biotechnology increased CEO Geordan Pursglove’s annual base salary from $240,000 to $360,000. This represents a $120,000 annual increase, implemented through a formal amendment to his employment agreement that was approved by the Compensation Committee and Board of Directors.

Who approved the CEO salary amendment at Lixte Biotechnology (LIXT)?

The CEO salary amendment was approved by Lixte Biotechnology’s Compensation Committee and Board of Directors. Their approval formalizes the change in Geordan Pursglove’s employment terms, and the executed Amendment is filed as Exhibit 10.1 and incorporated by reference into the company’s report.

Where can investors find details of Lixte’s CEO employment amendment?

Investors can review full details in Exhibit 10.1, titled Amendment to Employment Agreement dated March 18, 2026, between Lixte Biotechnology Holdings, Inc. and Geordan Pursglove. The company’s current report states that this exhibit is incorporated by reference into the main disclosure.

Filing Exhibits & Attachments

4 documents

Agreements & Contracts

Other Documents